Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11763712 | 0.81 | SLC6A2 (0.41) | SLC6A4SLC6A2 | |
| SCHEMBL18685611 | 0.80 | SLC6A4 (0.59) | SLC6A4SLC6A2 | |
| SCHEMBL28506253 | 0.80 | SLC6A4 (0.54) | SLC6A4SLC6A2 | |
| SCHEMBL7675986 | 0.78 | SLC6A4 (0.45) | SLC6A4SLC6A2 | |
| SCHEMBL4244509 | 0.78 | SLC6A4 (0.41) | SLC6A4SLC6A2P2RX7 | |
| SCHEMBL28345826 | 0.76 | SLC6A4 (0.48) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL6689686 | 0.76 | SLC6A4 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL13892321 | 0.74 | CDK4 (0.45) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL598296 | 0.74 | SLC6A2 (0.47) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL8573980 | 0.74 | SLC6A4 (0.53) | SLC6A4SLC6A2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | SCRIPPS RESEARCH INST (US) | 2023-03-09 | — | — | US | disclosed |
| CN-106456607-B | Pharmaceutical composition for topical administration | 齐阿科制药有限公司 | 2021-08-27 | — | — | CN | disclosed |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-12-27 | — | — | US | disclosed |
| US-10034858-B2 | Pharmaceutical composition for topical administration | Ziarco Pharma Ltd. (GB) | 2018-07-31 | — | — | US | disclosed |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170273945-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | Ziarco Pharma Ltd. (GB) | 2017-09-28 | — | — | US | disclosed |
| CN-106928247-A | Spiral shell oxindole compounds and its purposes as therapeutic agent | 泽农医药公司 | 2017-07-07 | — | — | CN | disclosed |
| US-9693995-B2 | Pharmaceutical composition for topical administration | ZIARCO PHARMA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1892239-A1 | Inhibitors of cytosolic phospholipase A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1451154-B1 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| CN-1617855-A | Cytosolic phospholipase A2Inhibitors | WYETH CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| EP-1451154-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth (US) | 2004-09-01 | — | — | EP | disclosed |
| US-6635771-B2 | Useful as intermediates in the synthesis of compounds having activity as chemical inhibitors of various phospholipase enzymes, particularly phospholipase A2 | WYETH | 2003-10-21 | — | — | US | disclosed |
| WO-2003048122-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2003-06-12 | — | — | WO | disclosed |
| US-4251659-A | Polyfluorohydroxyisopropyl-heterocyclic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034858-B2 | Pharmaceutical composition for topical administration | IL17A, IL5, CCL11 | SLC6A4 2123/4885SLC6A2 2329/4885P2RX7 38/4885 |
| US-20170273945-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | IL17A, IL5, CCL11 | SLC6A4 2123/4885SLC6A2 2329/4885P2RX7 38/4885 |
| US-10016394-B2 | PPARG modulators for treatment of osteoporosis | PPARG, PPARA, PPARD | SLC6A4 4433/4885SLC6A2 4460/4885P2RX7 614/4885 |
| US-20230072933-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SLC6A4 4231/4885SLC6A2 4244/4885P2RX7 591/4885 |
| US-20180369196-A1 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SLC6A4 4231/4885SLC6A2 4244/4885P2RX7 591/4885 |
| US-10744117-B2 | PPARG modulators for the treatment of osteoporosis | PPARG, PPARA, PPARD | SLC6A4 4231/4885SLC6A2 4244/4885P2RX7 591/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | SLC6A4 4231/4885SLC6A2 4244/4885P2RX7 591/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | SLC6A4 4701/4885SLC6A2 4148/4885P2RX7 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.